Thanks but no thanks: Why MSF is rejecting donated vaccines from Pfizer

By Molly Anders 12 October 2016

A vaccine vial and syringe. Photo by: NIAID / CC BY

Medecins Sans Frontieres announced Tuesday it will reject an offer of free pneumonia vaccine from pharmaceutical company Pfizer Inc, after the company declined to offer a more “sustainable and long-term” solution for acquiring the drug through discounted pricing, MSF officials told Devex.

“Until now, both Pfizer and [GlaxoSmithKline PLC] have said they would reduce the price, but have instead offered us donations,” said Judit Rius, U.S. manager and legal policy adviser for MSF's Access Campaign.

Gavi, the Vaccine Alliance, typically negotiates discounts directly with pharmaceutical companies for vaccines purchased by governments and organizations working in low-income countries. But middle- and upper-income countries don’t qualify for the discounts, and in some cases governments and organizations pay 30 to 50 times the discounted price, despite coping with protracted humanitarian crises, such as caring for large numbers of refugees in Greece, for example.

“The best way to provide medicines and access to diagnostics is through the normal supply chain mechanisms, that’s what we normally do,” Ruis told Devex in a phone interview. “These are the policies that global health organizations like the World Health Organization, UNICEF and Gavi recommend — not to accept in-kind donations from pharmaceutical companies but to negotiate prices.”

In September, GlaxoSmithKline announced it would discount the price for its vaccine for pneumococcal conjugate, currently the number one killer worldwide of children under 5. Pfizer, the only other producer of the vaccine, has not followed suit. MSF yesterday rejected the offer from Pfizer to donate a limited amount of the vaccine, hoping to spur Pfizer to join GSK in a more sustainable arrangement.

“Pfizer has yet to agree to talk to us about a price,” Rius said. “That’s why we’ve decided, after very difficult internal consultation as you can imagine, to say no to the donation in order to continue pursuing what we think is a more long-term strategy by becoming Pfizer customers,” she said.

Ruiz explained that while MSF welcomed the decision from GSK to negotiate a price, Pfizer’s reluctance exemplifies one of the greatest barriers to vaccination globally: unaffordability.

“These vaccines are very unaffordable for many countries, not just low-income countries, and [Pfizer doesn’t] want to lower the price for MSF because that would mean a precedent that could then be used for other countries and purchasers,” she said.

“We’re asking for a price quote, basically. Very simply, we’re just asking for a price quote to be able to purchase the vaccine and use it.”

Asked why Pfizer has yet to offer another, longer-term option for procuring the vaccine in humanitarian contexts, a spokesperson told Devex that the company is exploring other options.

“Pfizer works closely with governments and NGOs around the world to help provide countries with access to our vaccines and supports humanitarian emergency situations through a three-part approach, including product donations, cash grants and additional access solutions,” the spokesperson said in an email to Devex.

“We are engaged in discussions with our partners on potential new approaches to ensure as many people as possible have access to lifesaving vaccines,” the spokesperson said.

Making Markets Work is an online conversation to explore what’s being done to make global health care markets accessible to people at the base of the pyramid. Over 10 weeks, we will amplify the discussion around effective health financing, analyze key challenges blocking universal market access in the health care supply chain, and explore the key strategies to make markets more effective. Join us as we look at this important issue, and share your thoughts by tagging #MakingMarketsWork and @Devex.

About the author

Molly anders 400x400%2520%25281%2529
Molly Andersmollyanders_dev

Molly is a global development reporter for Devex. Based in London, she covers U.K. foreign aid and trends in international development. She draws on her experience covering aid legislation and the USAID implementer community in Washington, D.C., as well as her time as a Fulbright Fellow and development practitioner in the Middle East to develop stories with insider analysis.


Join the Discussion